Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

This study is investigating whether a specific genetic variation — the IL-4Ra R576 polymorphism — causes more severe atopic dermatitis (eczema) by altering how the skin's immune response works. IL-4Ra is a key receptor in the immune pathway that drives eczema, and this particular variant may make it harder for the body to control the inflammatory response, leading to worse skin disease. Participants will provide skin samples and blood for immune analysis to help researchers understand the underlying biology and potentially identify new treatment targets. You may be eligible if: - You are between 6 and 65 years old - You have a confirmed diagnosis of atopic dermatitis (eczema) meeting standard diagnostic criteria You may NOT be eligible if: - You are enrolled in another clinical trial - You have used immunosuppressive medications (e.g., steroids, cyclosporine, JAK inhibitors) within the past 4 weeks - You have received biologic treatments (e.g., dupilumab, omalizumab) within the past 16 weeks - You have used topical steroids or calcineurin inhibitors within the past 7 days - You have used antibiotics within the past 21 days - You have HIV, hepatitis B or C, tuberculosis, or a malignancy - You have severe ongoing illness (cardiovascular, renal, or autoimmune disease) Talk to your doctor to see if this trial is right for you.